LifeCycle Pharma to Webcast Presentation at UBS Global Life Sciences Conference

Investor Service Announcement no. 7/2007                                        

To: OMX Nordic Exchange	      Hørsholm, Denmark, September 18, 2007 

LifeCycle Pharma to Webcast Presentation at UBS Global Life Sciences Conference 

Summary: LifeCycle Pharma to Webcast Presentation at UBS Global Life Sciences   
Conference                                                                      

Hørsholm, Denmark, September 18, 2007; LifeCycle Pharma A/S (OMX:LCP), an       
emerging specialty pharmaceutical company focused on developing and             
commercializing differentiated versions of existing drugs in large therapeutic  
areas such as cardiovascular disease, organ transplantation and                 
immunosuppression, including recently Food and Drug Administration approved     
LCP-FenoChol, a fenofibrate for the treatment of hyperlipidemia and             
hypertriglyceridemia, announced today that Flemming Ornskov, President and Chief
Executive Officer, is scheduled to give a company presentation at the UBS Global
Life Sciences Conference on Tuesday, September 25, 2007 at 11:00 a.m. EDT (8:00 
a.m. in San Francisco; 5:00 p.m. in Denmark) at the Grand Hyatt in New York     
City.                                                                           

A live webcast of Flemming Ornskov's presentation will be accessible via the    
Company's web site at www.lcpharma.com. Participants are urged to log on to the 
web site 15 minutes prior to the scheduled start time to download and install   
any necessary audio software. A replay of the webcast will become available     
approximately 1 hour after the conclusion of the live presentation and will be  
accessible for 30 days.                                                         

About LifeCycle Pharma A/S (“LCP”):                                             
LCP, headquartered in Hørsholm, Denmark, is an emerging specialty pharmaceutical
company focused on developing and commercializing a portfolio of innovative     
products in therapeutic areas such as cholesterol management, hypertension,     
organ transplantation and autoimmune diseases. LCP's proprietary MeltDose®      
technology, offers lower dosing, reduced side effects, improved safety and      
patient compliance, and reduced product development costs and times.            
LCP-FenoChol, a fenofibrate for the treatment of hyperlipidemia and             
hypertriglyceridemia, is LCP's first FDA approved product (approved in August   
2007). LCP is listed on the OMX Nordic Exchange under the trading symbol        
(OMX:LCP). For further information, please visit www.lcpharma.com.              

Contact:                                                                        
Francesca M. DeMartino	                                                         
Director, Investor Relations & Corporate Communications                         
(201) 633-4729; FDM@lcpharma.com                                                

                                  ---oo0oo---